SecSonar.com

Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Industries Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Teva Pharmaceutical Industries Limited (TEVA) is a Drug Manufacturers - Specialty & Generic company based in IL with a market capitalization of $40.4B. Revenue grew 4.3% year-over-year and the company generated $1.1B in free cash flow. This page tracks TEVA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

IL · 37K employees · IPO Feb 16, 1982

Valuation

Valuation & price

$34.29 · as of May 17, 2026 · -5.6% vs 52w high

28.5

P/E ratio

Latest-FY diluted EPS

5.10

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$36.34$25.90$15.45Jul 25Dec 25Jul 26Jul 7, 25$16.85Jul 9, 25$16.71Jul 11, 25$16.40Jul 15, 25$16.04Jul 17, 25$16.31Jul 21, 25$16.31Jul 23, 25$16.58Jul 25, 25$16.54Jul 29, 25$16.54Jul 31, 25$15.45Aug 4, 25$15.69Aug 6, 25$16.01Aug 11, 25$16.42Aug 13, 25$17.21Aug 15, 25$17.86Aug 19, 25$17.56Aug 21, 25$18.80Aug 25, 25$18.12Aug 27, 25$18.05Aug 29, 25$18.38Sep 3, 25$18.76Sep 5, 25$18.95Sep 9, 25$19.68Sep 11, 25$19.89Sep 16, 25$18.68Sep 18, 25$18.45Sep 22, 25$18.87Sep 24, 25$19.27Sep 26, 25$18.34Sep 30, 25$20.20Oct 2, 25$20.05Oct 6, 25$19.96Oct 8, 25$20.21Oct 10, 25$20.03Oct 14, 25$20.11Oct 16, 25$19.63Oct 21, 25$18.99Oct 23, 25$19.02Oct 27, 25$19.61Oct 29, 25$20.23Oct 31, 25$20.48Nov 4, 25$20.46Nov 6, 25$24.46Nov 10, 25$24.26Nov 12, 25$25.83Nov 14, 25$25.41Nov 18, 25$24.84Nov 20, 25$24.28Nov 25, 25$24.99Nov 28, 25$26.89Dec 2, 25$26.88Dec 4, 25$28.41Dec 8, 25$28.33Dec 10, 25$29.80Dec 12, 25$29.79Dec 16, 25$30.10Dec 18, 25$30.32Dec 22, 25$31.19Dec 24, 25$31.74Dec 29, 25$31.56Jan 2, 26$30.95Jan 6, 26$32.11Jan 8, 26$32.51Jan 12, 26$32.79Jan 14, 26$32.64Jan 16, 26$31.76Jan 21, 26$31.41Jan 23, 26$31.81Jan 27, 26$32.53Jan 29, 26$33.07Feb 2, 26$35.52Feb 4, 26$34.96Feb 9, 26$34.47Feb 11, 26$34.31Feb 13, 26$33.98Feb 18, 26$34.11Feb 20, 26$34.22Feb 24, 26$33.92Feb 26, 26$33.77Mar 2, 26$33.77Mar 4, 26$32.91Mar 6, 26$31.05Mar 10, 26$31.52Mar 12, 26$29.30Mar 17, 26$30.09Mar 19, 26$29.44Mar 23, 26$28.77Mar 25, 26$29.46Mar 27, 26$28.74Mar 31, 26$30.12Apr 2, 26$30.08Apr 7, 26$29.33Apr 9, 26$30.96Apr 13, 26$31.15Apr 15, 26$31.61Apr 17, 26$32.40Apr 22, 26$31.22Apr 24, 26$30.64Apr 28, 26$31.62Apr 30, 26$35.07May 4, 26$35.35May 6, 26$36.34May 8, 26$35.73May 12, 26$35.81May 14, 26$35.31May 18, 26$34.03May 20, 26$34.32May 22, 26$34.07May 28, 26$34.52Jun 1, 26$34.64Jun 3, 26$32.83Jun 5, 26$34.19Jun 9, 26$34.45Jun 11, 26$34.56Jun 15, 26$33.69Jun 17, 26$32.56Jun 22, 26$32.20Jun 24, 26$34.22Jun 26, 26$33.21Jul 2, 26$34.64
$15.3852-week range$36.34
Loading valuation history…

Fundamentals

Key fundamentals

$40.4B

Market cap

4.3%

Revenue growth (YoY)

51.8%

Gross margin

$1.1B

Free cash flow (USD)

$13.8B

Net debt

1.6%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$21.9BFY 2017$22.4BFY 2018$18.9BFY 2019$16.9BFY 2020$16.7BFY 2021$15.9BFY 2022$14.9BFY 2023$15.8BFY 2024$16.5BFY 2025$17.3B
$21.9B$17.3B

Free cash flow by year

2016 → 2025

FY 2016$4.3BFY 2017$2.6BFY 2018$1.8BFY 2019$419.0MFY 2020$638.0MFY 2021$236.0MFY 2022$1.0BFY 2023$842.0MFY 2024$749.0MFY 2025$1.1B
$4.3B$1.1B

Gross margin by year

2021 → 2025

FY 202147.8%FY 202246.7%FY 202348.3%FY 202448.7%FY 202551.8%
47.8%51.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

10

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 29, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $322KShields Matthew · EVP, Global Operations · $321.5KJun 22, 2026Filing
  • Insider sellInsider Sell $3.6M · 10b5-1 PlanKalif Eliyahu Sharon · EVP, Chief Financial Officer · $3.6MJun 16, 2026Filing
  • Insider sellInsider Sell $211K · 10b5-1 PlanFrancis Richard D · President and CEO · $211.4KJun 8, 2026Filing
  • Insider sellInsider Sell $532K · 10b5-1 PlanShields Matthew · EVP, Global Operations · $532.3KJun 4, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 28, 2026Filing
  • Insider sellInsider Sell $5.5M · 10b5-1 PlanKalif Eliyahu Sharon · EVP, Chief Financial Officer · $5.5MMay 18, 2026Filing
  • Insider sellInsider Sell $1.5M · 10b5-1 PlanLippman Evan · EVP, Business Development · $1.5MMay 18, 2026Filing
  • Insider sellInsider Sell $1.1MDaniell Richard · EVP, Europe Commercial · $1.1MMay 7, 2026Filing
  • Insider sellInsider Sell $384KWeiss Amir · Chief Accounting Officer · $384.4KMay 7, 2026Filing
  • Insider sellInsider Sell $751KFox Christine · EVP, U.S. Commercial · $750.6KMay 4, 2026Filing

Questions

Frequently asked questions

What is Teva Pharmaceutical Industries Limited's market cap?

Teva Pharmaceutical Industries Limited (TEVA) has a market capitalization of $40.4B.

What is TEVA's P/E ratio?

TEVA trades at a price-to-earnings ratio of 28.5, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is TEVA's price-to-book (P/B) ratio?

TEVA trades at 5.10 times book value per share.

Are insiders buying TEVA stock?

SEC Form 4 filings show no open-market insider buys at Teva Pharmaceutical Industries Limited in the last 90 days (10 sells).

Same arena

Related companies in Drug Manufacturers - Specialty & Generic

HLN

Haleon plc

$40.5B

TAK

Takeda Pharmaceutical Company Limited

$50.4B

VTRS

Viatris Inc.

$18.8B

ELAN

Elanco Animal Health Incorporated

$12B

RDY

Dr. Reddy's Laboratories Limited

$11.4B

LNTH

Lantheus Holdings, Inc.

$6.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.